<DOC>
	<DOCNO>NCT00864526</DOCNO>
	<brief_summary>To compare relative bioavailability oxycodone HCl 5 mg / ibuprofen 400 mg tablet ( Actavis Elizabeth LLC , Lot No . PI-1565 ) COMBONOXÂ® tablet ( Forest Pharmaceuticals , Inc. , Lot No . 010550 ) healthy adult volunteer fast condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Single dose randomize , two-period , two-treatment , two-sequence crossover study fast condition compare equal dos test reference product . Official Title : A Relative Bioavailability Study Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1 . All subject select study least 18 year age . 2 . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow minimum : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT/AST , SGPT/ALT , bilirubin , alkaline phosphatase . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HIV Screen : ( prestudy ) HepatitisB , C Screen : ( prestudy ) Drugs Abuse Screen : ( prestudy checkin dose period ) Electrocardiograms participate subject record initiation study file subject 's case report form . 1 . Subjects history alcoholism drug addiction ( past 2 year ) , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . [ Subjects cholecystectomy eligible unless approve sponsor . ] 2 . Subjects whose clinical laboratory test value outside reference range may retested discretion clinical investigator . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . 3 . Subjects history allergic response class drug test exclude study . 4 . All subject urine/saliva sample assay presence drug abuse part clinical laboratory screening procedure checkin dose period . Subjects find urine/saliva concentration test drug allow participate . 5 . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . 6 . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . 7 . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom , IUD ) contraception course study ( first dose last blood collection ) allow participate . Subjects use implant injected hormonal contraceptive anytime 6 month prior study dose , use oral hormonal contraceptive contraceptive transdermal patch within 14 day dose allowed participate . 8 . All female subject screen pregnancy prior dose study period . Subjects positive inconclusive result withdrawn study . 9 . Subjects positive HIV hepatitis screen allow participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Oxycodone</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Healthy subject</keyword>
</DOC>